Key result
Patients prescribed varenicline in primary care were more likely to be abstinent 6 months after treatment than those prescribed nicotine replacement therapy (OR 1.46).
Why the study?
Does varenicline improve smoking cessation rates compared to nicotine replacement therapy in adult smokers in primary care?
Population
220,136 smokers aged ≥ 18 years in the UK prescribed smoking cessation treatment after September 1, 2006.
Comparison
First prescription of varenicline vs Nicotine replacement therapy (NRT)
Design
Cohort
Follow-up
2 years (primary outcome), up to 4 years
Authors
Loading...
Varenicline may be preferred over NRT for cessation in primary care; observational data leave open need for randomized confirmation.
Cohort (n=220,136)
Does varenicline improve smoking cessation rates compared to nicotine replacement therapy in adult smokers in primary care?
Odds Ratio: 1.46 (95% CI 1.42–1.5)
Varenicline is more effective than nicotine replacement therapy for smoking cessation in primary care, without evidence of increased mortality or morbidity.
Davies et al. (2020) conducted a cohort in Smoking (n=220,136). Varenicline vs. Nicotine replacement therapy was evaluated on Smoking cessation 6 months after treatment (OR 1.46, 95% CI 1.42 to 1.50). Patients prescribed varenicline in primary care were more likely to be abstinent 6 months after treatment than those prescribed nicotine replacement therapy (OR 1.46).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: